NEP INTERLONG (08329) has issued a supplementary announcement regarding a profit warning. Based on a further assessment of the Group's unaudited consolidated management accounts for the 2025 financial year and other currently available information, the Group anticipates that the profit attributable to its owners for the 2025 financial year will decrease by approximately 240% to 280% compared to the same period in 2024. The primary reason for this decline is an impairment loss on goodwill recognized in relation to the acquisition of Beijing NEP Zhongxin Pharmaceutical Co., Ltd.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments